Under the terms of the agreement, Codon will receive clinical milestone payments and royalties on net sales that may result from Merrimack’s development and commercialization of any protein product coming out of the collaboration.
Brian Baynes, president of Codon Devices, said: “This agreement reinforces the value of our BioLOGIC platform for the rapid development of superior proteins with desired properties in the important field of therapeutic products, in addition to other opportunities for enhanced products in next-generation biosecurity, improved agricultural products and engineered vaccines.”